Contraception in patients with systemic lupus erythematosus and antiphospholipid syndrome

Lupus

Volumn 23, Issue 12, 2014, Pages 1242-1245

  Sammaritano, L R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

antiphospholipid syndrome; Contraception; hormonal contraceptives; intrauterine device; long acting reversible contraception; systemic lupus erythematosus

Indexed keywords

CORTICOSTEROID; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; CONFERENCE PAPER; CONTRACEPTION; CONTRACEPTIVE DEVICE; FEMALE; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MATERNAL WELFARE; MENSTRUATION; OSTEOPOROSIS; PATIENT RISK; PREGNANCY; SUBDERMAL IMPLANT; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; PATHOPHYSIOLOGY; PROCEDURES;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; CONTRACEPTION; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY;

EID: 84908695767     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314528062     Document Type: Conference Paper

References (10)

1. Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012 ; 366: 1998-2007
2. Schwartz EB, Manzi S. Risk of unintended pregnancy among women with systemic lupus erythematosus. Arthritis Rheum. 2008 ; 59: 863-866
3. Yazdany J, Trupin L, Kaiser R, et al. Contraceptive counseling and use among women with systemic lupus: A gap in health care quality?. Arthritis Care and Research (Hoboken). 2011 ; 63: 358-365
4. Britto MT, Rosenthal SL, Taylor J, Passo MH. Improving rheumatologists' screening for alcohol and sexual activity. Arch Ped Adolesc Med. 2000 ; 154: 478-483
5. Mohammad A, Kilcoyne A, Bond U, Regan M, Phelan M. Methotrexate information booklet study 2008. Clin Exp Rheumatol. 2009 ; 27: 649-650
6. Yazdany J, Panopalis P, Gillis J, et al. A quality indicator set for systemic lupus erythematosus. Arthritis Care and Research. 2009 ; 61: 370-377
7. U.S. Medical Eligibility Criteria for Contraceptive Use, 2010, adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th ed. Morbidity and Mortality Weekly Report: June 18, 2010/59(RR04); 1-6.
8. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 ; 353: 2550-2558
9. Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med. 2005 ; 353: 2539-2549
10. Stringer EM, Kaseba C, Levy J, et al. A randomized trial of the intrauterine device versus hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol. 2007 ; 197: 144-e1-144.e8